Bavarian Nordic A/S 주요 수익원은 Life-Saving Vaccines이며, 최신 수익 발표에서 수익은 6,243,956,000입니다. 지역별로는 United States이 Bavarian Nordic A/S의 주요 시장이며, 수익은 2,697,034,000입니다.
Bavarian Nordic A/S은 수익성이 있나요?
no, 최신 재무제표에 따르면 Bavarian Nordic A/S의 순손실은 $0입니다.
Bavarian Nordic A/S에 부채가 있나요?
no, Bavarian Nordic A/S의 부채는 0입니다.
Bavarian Nordic A/S의 발행 주식은 몇 주인가요?
Bavarian Nordic A/S의 총 발행 주식은 0주입니다.
주요 통계
이전 종가
$9.35
시가
$9.68
일일 범위
$9.56 - $9.68
52주 범위
$8.67 - $13
거래량
1.9K
평균 거래량
4.2K
배당수익률
--
EPS(TTM)
14.24
시가총액
$2.2B
Bavarian Nordic A/S란 무엇인가요?
Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in research and development innovations, production and commercialization of life-saving vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. Bavarian Nordic A/S offers travel health products including cholera, rabies, tick-borne encephalitis and typhoid vaccines, as well as vaccines sold and distributed in selected markets on behalf of third parties. The firm deals with vaccines aimed at improving public health and preparedness. Bavarian Nordic A/S focuses on vaccine solutions that help address the threat of infectious diseases. The firm operates worldwide.